5th International mRNA Health Conference

November 1-2, 2017 / Berlin, Germany

The mRNA field keeps on growing and much has been achieved

The last year has been an exciting one for the mRNA field. More and more companies as well as academic groups are moving into the field, populate the mRNA landscape with new approaches and generate valuable mode of action data in a number of ways. Moreover, some mRNA companies already have started to publish clinical data and thereby provide evidence that the mRNA technology indeed works in humans. The proof of principle of this disruptive medical technology has undoubtedly been delivered, which represents a highly important milestone for the field. What a great success!

In spite of the great achievements we made, the field’s current phase is a critical one. We now need to define the right strategies for product development as well as for interactions within the field and with authorities. The next step we need to take is designing concrete products, combining tolerability and efficacy. Considering this, the core topics of this year’s conference are proofs of concept, clinical development, safety and efficacy – discussing these topics is essential for establishing best practices for successful mRNA product development.

In the framework of the 5th International mRNA Health Conference, we want to discuss how to take next steps and lay a common foundation to leverage the technology to a new level. This will allow rapid development of new products and establishing them in the market.

Our keynote speaker, extreme mountaineer Reinhold Messner, fits the current situation of the mRNA field very well. Since he achieved objectives that no one had considered to be reachable, his words will offer us a great source of inspiration. Let’s move mountains together!

We hope you will profit from the opportunities to gain new knowledge and enjoy being inspired by the distinguished selection of speakers we could gain for this year’s conference!

Rough time schedule

Wednesday, November 1, 2017

  • 9:00 am to 6:15 pm: Conference program with talks, poster session and panel discussion
  • 6:30 pm: Networking Evening

Thursday, November 2, 2017

  • 9:00 am to 4:30 pm: Conference program with talks and poster session

Sessions & Talks


Reinhold Messner, mountaineer, adventurer & explorer, Italy
Moving Mountains

Schraga Schwartz, Weizmann Institute of Science, Israel
Cracking the epitranscriptome

mRNA platforms

Stephen Hoge, Moderna Therapeutics, USA
The Clinical Development of mRNA Drugs and Vaccines

Ingmar Hoerr, CureVac, Germany
mRNA Therapeutics: Getting to Products

Ugur Sahin, BioNTech, Germany
Delivering Messages for Cancer Immunotherapy

mRNA Delivery & Design

Steve Dowdy, UCSD School of Medicine, USA
Delivery of RNA Therapeutics: Overcoming a Billion Years of Evolutionary Defenses

Christine Esau, Arcturus Therapeutics, USA
LUNAR-mRNA for protein replacement therapy

Tom Madden, Acuitas Therapeutics, Canada
Optimizing the Therapeutic Index of messenger RNA-Lipid Nanoparticles for Clinical Application

Chantal Pichon, Center for Molecular Biophysics, CNRS, France
Insights from intracellular trafficking studies for mRNA delivery and bioproduction

Alexandra Stolzing, Loughborough University, UK
mRNA for cell reprogramming

Renata Grzela, University of Warsaw, Poland (Poster talk)
Stability, translational efficiency of capped mRNA and induction of antiviral protein IFIT1 in HEK293 cells

Katrien Remaut, Ghent University, Belgium (Poster talk)
Advanced microscopy methods to elucidate bottlenecks in lipid- and polymer assisted mRNA delivery: finding the balance

Asha K Patel, Massachusetts Institute of Technology, USA (Poster talk)
Chemically versatile, degradable nano-carriers for systemic and localized delivery of mRNA to the lung

Molecular Therapy, Antibodies & Protein Replacement

Regina Fritsche-Danielson, AstraZeneca, Sweden
VEGF-A Modified mRNA Therapy for Treatment of Chronic Skin Ulcers and Ischemic Heart Disease. From Preclinical Studies to Phase2A

Keiji Itaka, Tokyo Medical and Dental University, Japan
mRNA-based therapy for intractable diseases and regenerative medicine

Michael Kormann, University of Tübingen, Germany
Chemically modified CFTR mRNA normalizes critical lung function parameters in vivo

Lior Zangi, Icahn School of Medicine at Mount Sinai, USA
Cardiomyocytes Specific Modified mRNA of Cell Cycle Inducer Promote Mammalian Cardiac Regeneration Post Injury

Lianne Smith, Translate Bio, USA
mRNA Therapeutics for the Treatment of Rare Diseases

Ellese Carmona, Harvard Medical School, USA (Poster talk)
Circular mRNA as a Novel Template for Therapeutic Gene Transfer

Robert Overell, PhaseRx, USA (Poster talk)
Targeted mRNA delivery to the liver as a treatment for ornithine transcarbamylase deficiency (OTCD)

Cancer Therapy

Hayat Bähr-Mahmud, BioNTech, Germany
Elimination of solid tumors in mice by mRNA-encoded bispecific antibodies

Karine Breckpot, Vrije Universiteit Brussel, Belgium
TriMix mRNA-based cancer vaccines

Stefaan De Koker, eTheRNA Immunotherapies, Belgium
Type I IFN and T-cell immunity to mRNA vaccines: good, bad or just expandable?

Smita Nair, Duke University School of Medicine, USA
RNA-based Cancer Vaccines

Irina Tcherepanova, Argos Therapeutics, USA (Poster talk)
Interim analysis of Rocapuldencel-T testing in the ongoing Phase 3 study in mRCC patients

Vaccines against Infectious Diseases

Michela Brazzoli, GSK Vaccines, Italy
Self-amplifying mRNA-based vaccine promotes different types of immune responses correlating with protection in influenza animal models

Justin Richner, IIT Research Institute (IITRI), USA
A novel mRNA vaccine protects against Zika virus in a mouse model

Jörg Vogel, University of Würzburg, Germany
RNA-based Infection Research

Drew Weissman, University of Pennsylvania, USA
Nucleoside-modified mRNA-lipid nanoparticle vaccine platform induces potent T follicular helper and antibody responses

Frank Baehner, CureVac, Germany
mRNA based rabies vaccine: From first clinical proof of principle towards competitive product candidates

Hanne Huysmans, Ghent University, Belgium (Poster talk)
Comparison of the expression kinetics and immunostimulatory activity of replicating mRNA, non-replicating mRNA and pDNA after intradermal electroporation in pigs

Product Development

Arlen Avakian, Alexion, USA
mRNA, Developing a New Therapeutic Modality for the Treatment of Rare Diseases

Thomas Hinz, Paul-Ehrlich-Institut, Germany
Regulatory Aspects of RNA-Based Medicines

Klaus T. Preissner, Justus-Liebig-Universität Gießen, Germany
RNase1 administration as an effective and safe regimen against damaging extracellular RNA in cardiovascular diseases

Janos Szebeni, Semmelweis University, Hungary
Immune reactivity of lipid nanoparticle formulations of nucleic acid-based therapeutics: animal models